Targeted drug therapy has played an important role in improving the cure or survival rate of cancer patients, as well as improving their quality of life. However, the cure rate of targeted drugs for breast cancer is related to whether the patient is sensitive to the targeted drugs, the clinical stage and pathological type of the tumor, as well as the patient’s physical condition. If targeted drug therapy is used along with surgery, the clinical cure rate of early-stage breast cancer can generally reach about 80%; the clinical cure rate of mid-stage breast cancer is about 50%; advanced breast cancer patients are generally incurable, but with active treatment, the 5-year survival rate can reach about 20%, and the overall average survival time is 2~3 years. This treatment method of targeted therapy is less invasive and has less toxic side effects, especially for patients with early stage breast cancer. For early-stage breast cancer, a combination of surgical resection and targeted therapy is recommended in combination with the patient’s condition. In addition, patients can also combine radiotherapy, chemotherapy and endocrine therapy during the application of targeted drug treatment, which can make the target more clear and the effect more precise, thus improving the cure rate as well as the survival of patients. Patients should pay attention to regular review during and after treatment to prevent recurrence.